This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Abletshauser, C. Articles by Hanefeld, M. Search for Related Content Social Bookmarking                         What's this?

Effect of nateglinide and glimepiride in reducing postprandial hyperglycaemia in patients with type 2 diabetes mellitus

Novartis Pharma GmbH, Nurnberg, Germany

Patrick Brunel

Novartis Pharma AG, Basel, Switzerland

Klaus-Henning Usadel

Department of Medicine, Johann Wolfgang Goethe University, Frankfurt

Markolf Hanefeld

Zentrum für Klinsiche Studien, GWT der TU Dresden, Germany, hanefeld{at}gwt-tud.de

Aim — The purpose of this study was to compare the effect of nateglinide on two-hour post-meal glucose levels with that of glimepiride in patients with type 2 diabetes mellitus. Methods — Glucose and insulin levels were measured during 14-hour profiles (comprising three meal challenges) and intravenous glucose tolerance tests performed before and after five-weeks of treatment with nateglinide (120 mg, a.c.) or glimepiride (1 mg, o.d.) in a randomised, two-centre, double-blind, crossover study in 26 patients with type 2 diabetes and fasting initial glucose levels < 13.9 mmol/L. Results — Mean two-hour postprandial glucose levels were significantly lower during nateglinide treatment than during glimepiride treatment (9.46 vs. 10.00 mmol/L, respectively; p<0.05). The 14-hour incremental glucose area under the curve was -2.2 mmol•h/L during nateglinide treatment and +6.2 mmol•h/L during glimepiride treatment (p<0.01). Nateglinide improved both the early insulin response during meals and the acute insulin response during intravenous glucose tolerance tests, restoring the biphasic insulin secretion pattern. Both insulin secretagogues improved intravenous glucose tolerance relative to the pre-treatment period, but only nateglinide restored a biphasic insulin profile. Conclusions — By restoring a more physiological post-load insulin response, nateglinide is more effective than glimepiride in controlling postprandial glucose excursions.

Key Words: glimepiride • nateglinide • postprandial hyperglycaemia • type 2 diabetes mellitus.

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 2, 93-99 (2005)
DOI: 10.1177/14746514050050020701


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?